These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 15071285

  • 41. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
    Carbonell-Estrany X.
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
    [Abstract] [Full Text] [Related]

  • 42. [Impact of a targeted educational intervention on respiratory syncytial virus bronchiolitis prevention in full-term and preterm infants].
    Bernard L, Lecomte B, Pereira B, Proux A, Boyer A, Sautou V.
    Arch Pediatr; 2015 Feb; 22(2):146-53. PubMed ID: 25534557
    [Abstract] [Full Text] [Related]

  • 43. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.
    Prais D, Schonfeld T, Amir J, Israeli Respiratory Syncytial Virus Monitoring Group.
    Pediatrics; 2003 Sep; 112(3 Pt 1):548-52. PubMed ID: 12949282
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    Meissner HC, Long SS, American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
    Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. The effect of an interventional program on adherence to the american academy of pediatrics guidelines for palivizumab prophylaxis.
    Afghani B, Ngo T, Leu SY, Wu FL, Cecilio M, Aron-Johnson P, Zeitany R, Sills J, Amin A.
    Pediatr Infect Dis J; 2006 Nov; 25(11):1019-24. PubMed ID: 17072124
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Palivizumab for respiratory syncytial virus prophylaxis.
    Sandritter T.
    J Pediatr Health Care; 1999 Nov; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Implementation of American Academy of Pediatrics guidelines for palivizumab prophylaxis in a pediatric hospital.
    Zembles TN, Gaertner KM, Gutzeit MF, Willoughby RE.
    Am J Health Syst Pharm; 2016 Mar 15; 73(6):405-8. PubMed ID: 26953285
    [Abstract] [Full Text] [Related]

  • 52. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
    Resch B.
    Hum Vaccin Immunother; 2017 Sep 02; 13(9):2138-2149. PubMed ID: 28605249
    [Abstract] [Full Text] [Related]

  • 53. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.
    Cochrane Database Syst Rev; 2013 Apr 30; (4):CD006602. PubMed ID: 23633336
    [Abstract] [Full Text] [Related]

  • 54. Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada.
    Paes B, Cole M, Latchman A, Pinelli J.
    Curr Med Res Opin; 2009 Sep 30; 25(9):2191-6. PubMed ID: 19604126
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.
    Parnes C, Guillermin J, Habersang R, Nicholes P, Chawla V, Kelly T, Fishbein J, McRae P, Goessler M, Gatti A, Calcagno JA, Eki C, Harris KA, Joyave J, McFarland K, Protter P, Sullivan M, Stanford A, Lovett N, Ortiz M, Rojas S, Cyrus S, Cyrus J, Cohen S, Buchin D, Riordan L, Zuniga M, Shah R, Minard C, Quintin A, Douglas G, van Houten J, Freutner S, Chartrand S, Nowatzke P, Romero J, Rhodes T, Benoit M, Walter E, Walker L, DeBonnett L, Cross M, Free T, Martin S, Shank K, Guedes B, Atkinson LA, Halpin GJ, Rouse K, Hand I, Geiss D, Marshall JR, Burleson L, Boland J, Seybold K, Hunter V, Unfer S, Schmucker J, Gley M, Marcus M, Thompson P, Milla P, Young C, Zanni R, Zinno V, Fetter-Zarzeka A, Busey A, Sokunbi MA, Airington S, Richard N, Muraligopal V, Lewis S, Weber FT, Giordano BP, Linehan D, Roach J, Davis R, Rzepka AA, Booth T, Smeltzer D, Walsh J, Arispe E, Rowley R, Bolling C, Botts T, Haskett K, Raby D, Batiz E, Gelfand A, Farrell L, Butler S, Colby L, Schochet P, Bentler J, Hirsch D, Wilkinson L, Aaronson A, Bennett E, Wingate J, Quinn D, Komendowski K, Deckard M, Frogel M, Nerwen C, Copenhaver S, Prater M, Wolsztein J, Mackey K, Benbow M, Naranjo M, Hensley S, Hayes C, Sadeghi H, Lawson SM, McCall M, Combs K, Ledbetter J, Sarnosky K, Swafford C, Speer M, Barton WJ, Mink JW, Lemm D, Hudak M, Case E, Rowen J, Fuentes S, Pane C, Richardson L, Chavarria C, Cassino D, Ghaffari K, Carroll C, Lee H, Guclu L, Johnson C, Blum V, Boron ML, Sorrentino M, Hirsch RL, Van Veldhuisen PC, Smith C, Palivizumab Outcomes Registry Study Group.
    Pediatr Pulmonol; 2003 Jun 30; 35(6):484-9. PubMed ID: 12746948
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-Optimal Protection Against Respiratory Syncytial Virus.
    Weinberger DM, Warren JL, Steiner CA, Charu V, Viboud C, Pitzer VE.
    Clin Infect Dis; 2015 Aug 15; 61(4):506-14. PubMed ID: 25904370
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.